Treatment Outcome of Vascular Depression

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This 12-week study will evaluate the effectiveness of sertraline (Zoloft®) for treatment of depression associated with small vascular lesions in the brain (vascular depression).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Collaborators: Duke University; National Institute of Mental Health (NIMH)
• Treatments: Sertraline

Criteria

Inclusion Criteria:

1. Ages 60+

2. DSM-IV criteria for MDD

3. Hamilton Depression Rating Scale score >18

4. No MRI contraindications, e.g. foreign metallic implants, pacemaker

5. Medication free of any psychotropic drug except as otherwise noted for set washout period (see D.2.1)

6. Mini Mental Status Exam score <21

7. No unstable medical disorders (requiring immediate medical attention)

8. Ability to give informed consent

9. English speaking

Exclusion Criteria:

1. Age <60

2. Does not meet DSM-IV criteria for MDD

3. Hamilton Depression Rating Scale score <18

4. MRI contraindications e.g. foreign metallic implants, pacemaker

5. Psychotropic drug use other than zolpidem and lorazepam, prn within 2 weeks of entry

6. Mini Mental Status Exam score >21, or known primary neurological disorders including Dementia of the Alzheimer type, Parkinson's Disease, multiple sclerosis, seizure disorder.

7. Unstable medical disorders, uncorrected hypothyroidism, or any condition that in the investigators opinion makes the patients unsuitable for a trial

8. Cannot give informed consent

9. Does not speak English